The suggestion that the activation of the HGF/MET pathway under the influence of various factors (hypoxia, fibroblasts) may contribute to a lower sensitivity of melanoma cells to targeted therapies is also confirmed by the observations of an increased level of HGF (mRNA) expression in samples progressing during the therapy compared to samples before therapy [41]. The gene discussed is MET; the disease is melanoma.